Innovations in the treatment of invasive cervical cancer

被引:16
作者
Stehman, FB
Rose, PG
Greer, BE
Roy, M
Plante, M
Penalver, M
Jhingran, A
Eifel, P
Montz, F
Wharton, JT
机构
[1] Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA
[2] MetroHlth Med Ctr, Dept Gynecol Oncol, Cleveland, OH USA
[3] Univ Washington, Sch Med, Dept Gynecol Oncol, Seattle, WA 98195 USA
[4] Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ, Canada
[5] Univ Miami, Dept Gynecol Oncol, Sch Med, Miami, FL 33152 USA
[6] Johns Hopkins Hosp & Med Inst, Dept Gynecol & Obstet, Baltimore, MD USA
[7] Johns Hopkins Hosp & Med Inst, Dept Surg, Baltimore, MD USA
[8] Johns Hopkins Hosp & Med Inst, Dept Oncol, Baltimore, MD USA
[9] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
关键词
D O I
10.1002/cncr.11676
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Invasive cervical cancer is characterized by basement membrane-invading lesions capable of metastasizing through the lymphatic and vascular systems. Treatment methods were reviewed by panelists at the Second International Conference on Cervical Cancer (Houston, TX, April 11-14, 2002), and new opportunities for translational research were discussed. Reviews encompassed hysterectomy with or without lymph node dissection or cervical conization in cases with microinvasion and radical trachelectomy with or without lymph node dissection as fertility-sparing surgery. Chemoradiation is used to treat advanced cervical malignancies, and the risks and benefits of radiotherapy are significant. Pelvic exenteration is used to treat certain types of recurrences. Use of the Miami pouch for continent urinary diversion was highlighted. Gynecologic oncologists expect novel in vivo imaging techniques currently being developed to help guide therapy choices within the next decade. The most significant research priorities are large group-randomized trials involving fertility-sparing procedures and the management of microinvasive carcinoma (MICA); better identification of candidates for chemoradiation; and the development of innovative approaches to exenteration. Improving diagnostic technologies, refining the criteria by which therapies are chosen, and preserving fertility remain challenges in selecting the most appropriate treatment for invasive cervical cancer. Research advances in both diagnosis and treatment are expected to improve therapy and outcomes. (C) 2003 American Cancer Society.
引用
收藏
页码:2052 / 2063
页数:12
相关论文
共 51 条
[1]   Urinary complications of Miami pouch: Trend of conservative management [J].
Angioli, R ;
Estape, R ;
Cantuaria, G ;
Mirhashemi, R ;
Williams, H ;
Martin, J ;
Penalver, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (02) :343-348
[2]   Conservative treatment after miscarriage of one fetus in multifetal pregnancies - Report of three cases and review of the literature [J].
Antsaklis, A ;
Daskalakis, G ;
Papageorgiou, I ;
Aravantinos, D .
FETAL DIAGNOSIS AND THERAPY, 1996, 11 (05) :366-372
[3]  
Benedet J L, 2001, J Epidemiol Biostat, V6, P7
[4]   Topotecan in squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group [J].
Bookman, MA ;
Blessing, JA ;
Hanjani, P ;
Herzog, TJ ;
Andersen, WA .
GYNECOLOGIC ONCOLOGY, 2000, 77 (03) :446-449
[5]   A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix [J].
Burnett, AF ;
Roman, LD ;
Garcia, AA ;
Muderspach, LI ;
Brader, KR ;
Morrow, CP .
GYNECOLOGIC ONCOLOGY, 2000, 76 (01) :63-66
[6]   Concomitant irradiation and dose-escalating carboplatin for locally advanced carcinoma of the uterine cervix - An updated report [J].
Corn, BW ;
Micaily, B ;
Dunton, CJ ;
Heller, P ;
Valicenti, RK ;
Anderson, L ;
Hernandez, E .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (01) :31-35
[7]  
Cosin JA, 1998, CANCER, V82, P2241, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2241::AID-CNCR20>3.0.CO
[8]  
2-T
[9]  
Covens A, 1999, CANCER, V86, P2273, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2273::AID-CNCR15>3.0.CO
[10]  
2-C